Nuvation Bio (NUVB) Competitors $2.14 -0.05 (-2.28%) As of 03:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. MOR, PTGX, MTSR, XENE, MLTX, IMVT, HCM, AMRX, OGN, and MIRMShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include MorphoSys (MOR), Protagonist Therapeutics (PTGX), Metsera (MTSR), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. MorphoSys Protagonist Therapeutics Metsera Xenon Pharmaceuticals MoonLake Immunotherapeutics Immunovant HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Nuvation Bio (NYSE:NUVB) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations. Which has more risk and volatility, NUVB or MOR? Nuvation Bio has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Which has preferable valuation and earnings, NUVB or MOR? Nuvation Bio has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M92.06-$75.80M-$2.35-0.91MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Do institutionals and insiders hold more shares of NUVB or MOR? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to NUVB or MOR? In the previous week, Nuvation Bio had 15 more articles in the media than MorphoSys. MarketBeat recorded 15 mentions for Nuvation Bio and 0 mentions for MorphoSys. Nuvation Bio's average media sentiment score of 1.02 beat MorphoSys' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the media. Company Overall Sentiment Nuvation Bio Positive MorphoSys Neutral Does the MarketBeat Community prefer NUVB or MOR? Nuvation Bio received 31 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 81.16% of users gave Nuvation Bio an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes5681.16% Underperform Votes1318.84%MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Is NUVB or MOR more profitable? Nuvation Bio has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Nuvation Bio's return on equity of -21.89% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% MorphoSys -226.79%-694.31%-22.55% Do analysts recommend NUVB or MOR? Nuvation Bio currently has a consensus price target of $7.83, suggesting a potential upside of 266.04%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNuvation Bio beats MorphoSys on 18 of the 19 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$724.77M$6.27B$5.25B$19.43BDividend YieldN/A3.02%4.99%3.93%P/E Ratio-0.998.7326.6435.21Price / Sales92.06269.18399.5335.00Price / CashN/A65.8538.3117.51Price / Book0.786.256.684.71Net Income-$75.80M$143.73M$3.22B$1.02B7 Day Performance5.42%0.75%1.25%4.22%1 Month Performance5.68%5.28%5.98%9.73%1 Year Performance-35.25%-6.86%13.85%5.17% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio3.5467 of 5 stars$2.14-2.3%$7.83+266.0%-35.0%$724.77M$7.87M-0.9960Earnings ReportAnalyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4298 of 5 stars$45.27+5.4%$65.44+44.6%+51.0%$2.80B$207.80M17.02120Analyst RevisionPositive NewsMTSRMetseraN/A$26.38+10.5%$47.00+78.2%N/A$2.77BN/A0.0081Earnings ReportNews CoverageGap UpXENEXenon Pharmaceuticals2.5223 of 5 stars$35.85+2.4%$56.22+56.8%-26.9%$2.75B$9.43M-12.71210Earnings ReportAnalyst ForecastNews CoveragePositive NewsHigh Trading VolumeMLTXMoonLake Immunotherapeutics3.1793 of 5 stars$40.18+4.4%$80.50+100.3%-7.6%$2.57BN/A-31.152Earnings ReportAnalyst ForecastNews CoveragePositive NewsIMVTImmunovant2.623 of 5 stars$14.55+3.8%$38.33+163.5%-53.1%$2.47BN/A-5.55120Positive NewsHCMHUTCHMED2.335 of 5 stars$13.92-2.0%$19.00+36.5%-39.7%$2.43B$630.20M0.001,760Analyst DowngradePositive NewsAMRXAmneal Pharmaceuticals3.032 of 5 stars$7.60+2.6%$11.50+51.3%+11.8%$2.36B$2.83B-11.187,600Analyst DowngradeGap UpOGNOrganon & Co.4.9094 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.13 of 5 stars$45.57+2.9%$59.00+29.5%+82.7%$2.25B$379.25M-22.56140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies MorphoSys Alternatives Protagonist Therapeutics Alternatives Metsera Alternatives Xenon Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Immunovant Alternatives HUTCHMED Alternatives Amneal Pharmaceuticals Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | SponsoredBITCOIN Liquidity pools are the backbone of crypto—and right now, they’re exploding with activity. By providing liqui...Awesomely, LLC | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NUVB Stock Free NUVB Stock Alerts